Dev4All and Pharmaseed Join Forces in Commercial Cooperation to Boost Preclinical Development Services
To drive innovative solutions and accelerate drug development To offer clients comprehensive services tailored to their scientific needs To strengthen global competitiveness in preclinical R&D
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127719655/en/
Dev4All and Pharmaseed Join Forces in Commercial Cooperation (Graphic: Business Wire)
Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research Organization (CRO) with over 20 years of expertise in preclinical drug development.
This partnership combines the strengths of both organizations to offer an integrated, end-to-end approach for preclinical development. Together, Dev4All and Pharmaseed aim to deliver comprehensive and competitive solutions that accelerate drug development and address the complexities of today’s R&D landscape.
With over two decades of experience in CRO services and ten years advancing drug development candidates from TRL3 to TRL5, this close cooperation provides tailored preclinical support, cutting-edge laboratory capabilities, and strategic expertise, complementing clients’ R&D efforts worldwide.
Revital Rattenbach, Executive Chair of Dev4All, said: "I am thrilled about the new collaboration between Dev4All and Pharmaseed, which marks an exciting step forward in our shared commitment to innovation. This commercial cooperation empowers us to scale our capabilities, elevate our global impact, and deliver tailor-made solutions that meet our client's needs while maintaining the highest standards of scientific rigor."
Shmuel Landau, Co-CEO of Pharmaseed, said: "This collaboration with Dev4All is an excellent opportunity to expand our European presence and integrate our comprehensive preclinical solutions with DEV4ALL innovative R&D platform. Together, we are committed to deliver top-tier services, ensuring clients achieve their scientific and clinical milestones."
About Dev4All:
Dev4All, powered by 4P-Pharma, is an R&D booster designed to provide a wide range of preclinical solutions. With a decade-long foundation in preclinical research, Dev4All is committed to transforming innovative ideas into clinical-stage candidates through collaboration and scientific excellence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241127719655/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
28th World Investment Conference in Riyadh Concludes with Calls for International Collaboration, Innovation, and Sustainability29.11.2024 05:37:00 CET | Press release
International collaboration, innovation and sustainability were the key themes of the 28th World Investment Conference (WIC28), hosted by Invest Saudi and The World Association of Investment Promotion Agencies (WAIPA) that concluded in Riyadh this week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128896366/en/ H.E. Khalid A. AlFalih, Minister of Investment, Saudi Arabia, closes the World Investment Conference in Riyadh, Saudi Arabia (Photo: AETOSWire) Commenting on the success of the event, H.E. Khalid A. Al-Falih, Saudi Minister of Investment said, "This event was held under the auspicious patronage of His Royal Highness Crown Prince and Prime Minister, Mohammed bin Salman bin Abdulaziz Al Saud to whom we extend our deepest gratitude for his visionary leadership and unwavering support. “Over the past three days, we discussed the critical challenges facing global investment and reviewed the boundless opportunities that
Aramco Unveils Recycled Basketball Courts, Boosting "Shoot for the Future" Project29.11.2024 02:45:00 CET | Press release
Aramco, one of the world’s leading integrated energy and chemicals companies, has unveiled the first three renovated community basketball courts on Tuesday in Dongdan basketball community, Beijing, China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128606707/en/ Aramco has unveiled the first three renovated community basketball courts on Tuesday in Beijing, China. (Photo: Business Wire) These courts, which were built with innovative and advanced materials, with the flooring made partly from recycled plastic, are part of Aramco’s “Shoot for the Future” basketball court revamp project, with the goal of injecting new energy into community basketball in China. The project also aims to showcase the increasingly important role that advanced materials can play in a circular carbon economy, while helping with Aramco’s objective to support and empower communities and youth through sports, and to bring green development and recy
VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond29.11.2024 01:00:00 CET | Press release
LVGL adds VeriSilicon’s 3D and VGLite 2.5D GPUs support to its library for a wide range of embedded applications VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand graphic processing capabilities for a wide range of embedded applications. As one of the first providers of 3D GPU technology for the LVGL ecosystem, VeriSilicon will contribute to advancing 3D rendering capabilities within the LVGL library. LVGL is the most popular free and open-source embedded graphics library to create beautiful User Interfaces (UIs) for any Microcontroller Units (MCUs), Micro Processor Units (MPUs), or display type. By integrating VeriSilicon’s low-power and high-performance GPU solutions into LVGL’s graphics ecosystem, it offers developers the ability to rapidly deliver
MAG Group Holding Real Estate Portfolio Reaches USD 11.9 Billion28.11.2024 11:47:00 CET | Press release
MAG Group Holding, the multinational conglomerate incorporating different companies serving diverse sectors, announced its portfolio of current and under development projects across its different real estate subsidiaries has reached USD 11.9 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128995871/en/ Moafaq Al Gaddah, Founder and Chairman of MAG Group Holding (Photo: AETOSWire) MAG Group Holding’s real estate subsidiaries include MAG Lifestyle Development, Keturah, Invest Group Overseas (IGO), MBL, Shoumous, Art of Living Mall and MAG Leasing for warehouses. In his comments, Moafaq Al Gaddah, Founder and Chairman of MAG Group Holding, said: "The UAE's real estate sector is witnessing unprecedented demand, driven by the strategic vision and initiatives of our wise leadership. The government’s ongoing efforts to foster a favorable investment climate have made the UAE a preferred investment destination for global i
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis28.11.2024 07:00:00 CET | Press release
Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1 Data were consistent with OLYMPIA 2 trial results, reinforcing the potential of nemolizumab monotherapy to demonstrate rapid and sustained improvements in core signs and symptoms of prurigo nodularis: skin lesions, itch and sleep disturbance – at Week 16 and Week 241,2 In the OLYMPIA 1 trial, a significantly higher proportion of nemolizumab-treated patients achieved an itch-free or nearly itch-free state as early as Week 4 compared to those receiving placebo1 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that is known to drive key signs and symptoms of prurigo nodularis3,4 Galderma (SWX:GALD) today announced that full
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom